Pathogenicity of Human anti-PLA2R1 Antibodies in Minipigs: A Pilot Study

January 2023 | New Publication

Reinhard L et al., J Am Soc Nephrol 2023

Using minipigs as a model organism, this proof-of-concept report from the Laboratory for Personalized Treatment of Immune-Mediated Kidney Diseases for the first time demonstrates the direct pathogenicity of human-derived anti-PLA2R1 antibodies.

For further information visit:
JASN - Pathogenicity of Human anti-PLA2R1 Antibodies in Minipigs: A Pilot Study

Back to News & Career

More articles in this category

April 2024 | News

Advanced ERC Grant - CureFSGS

February 2024 | New Publication

Ibrutinib-associated focal segmental glomerulosclerosis and the impact of podocin mutations in chronic lymphocytic leukemia

January 2024 | New Publication

An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells

December 2023 | New Publication

Metabolic Communication by SGLT2 Inhibition

Martinistraße 52
Campus Research N27
20246 Hamburg Germany
This email address is being protected from spambots. You need JavaScript enabled to view it.

Calculate route

Services

University Medical Center Hamburg - Eppendorf

III. Department of Medicine